Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7698539 | 0.90 | MAPK1 (0.53) | MAPK1HTTGAANPSR1PAX8 | |
| SCHEMBL7476806 | 0.79 | ALDH1A1 (0.46) | MAPK1HTTGAAMAPTSMN1; SMN2 | |
| SCHEMBL7476808 | 0.79 | ALDH1A1 (0.46) | MAPK1HTTGAAMAPTSMN1; SMN2 | |
| SCHEMBL6843749 | 0.72 | MAPK1 (0.35) | MAPK1HTTMAPTSMN1; SMN2LMNA | |
| SCHEMBL11850324 | 0.71 | MAPK1 (0.70) | MAPK1HTTGAANPSR1PAX8 | |
| SCHEMBL6846139 | 0.70 | MAPK1 (1.00) | MAPK1HTTGAANPSR1PAX8 | |
| SCHEMBL12176671 | 0.70 | HPGD (0.43) | MAPK1HTTGAANPSR1MAPT | |
| SCHEMBL6203512 | 0.70 | TBXA2R (0.40) | MAPK1HTTGAANPSR1MAPT | |
| SCHEMBL7476335 | 0.69 | MAPT (0.40) | MAPK1HTTNPSR1MAPTSMN1; SMN2 | |
| SCHEMBL8328864 | 0.69 | ALDH1A1 (0.47) | MAPK1HTTGAANPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077625-A1 | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake | PHARMACIA CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20020183307-A1 | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake | G.D. SEARLE LLC | 2002-12-05 | — | — | US | disclosed |
| WO-2002008211-A2 | BENZOTHIAZEPINES AND THEIR USE AS ANTIHYPERLIPIDEMICS | G.D. SEARLE, LLC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077625-A1 | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake | SLC10A1, ABCB11, SLC10A2 | MAPK1 3177/4885HTT 2513/4885GAA 1782/4885 |
| US-20020183307-A1 | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake | SLC10A1, SLC10A2, ABCB11 | MAPK1 3076/4885HTT 3139/4885GAA 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.